• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎与结核病合并感染

Co-infection of COVID-19 and Tuberculosis.

作者信息

Kılıç Lütfiye, Altın Sedat, Gönenç Ortaköylü Mediha, Kanmaz Zehra Dilek, Tutar Tayjen, Özkan Gülcihan Zehra

机构信息

Department of Chest Diseases, Koç University Hospital, İstanbul, Turkey.

Department of Chest Diseases, University of Health Sciences, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey.

出版信息

Turk Thorac J. 2022 Jan;23(1):58-62. doi: 10.5152/TurkThoracJ.2022.21045.

DOI:10.5152/TurkThoracJ.2022.21045
PMID:35110202
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9450003/
Abstract

OBJECTIVE

Tuberculosis and COVID-19 diseases occur more frequently in people with similar risk factors. This study aimed to share the data on active tuberculosis patients during the severe acute respiratory syndrome coronavirus 2 pandemic.

MATERIAL AND METHODS

The registration information of TB outpatient clinic between November 1, 2019, and April 20, 2020, was screened. A 7-question survey was administered to the patients who were diagnosed with active tuberculosis and who were agreed to participate in the study.

RESULTS

A total of 309 patients with active tuberculosis were evaluated, the average age of the patients was 42.5 ± 18.5 years, and 70% were male. The percentage of having at least 1 comorbidity was 30.4%. The percentage of coronavirus disease 2019 disease in our study population was 1.9%; none of the patients of coronavirus disease 2019 were taken into the intensive care unit or dead due to clinical deterioration and/or respiratory failure. On the other hand, in this process it was announced that 146 457 cases were diagnosed with coronavirus disease 2019 throughout the country, of which 72% had inpatient treatment, 2% died, and 944 patients were still being treated in the intensive care unit, of which 490 were intubated. The positivity ratio of the reverse transcription-polymerase chain reaction test was 20.0% in the study group, while 20.3% in the İstanbul population.

CONCLUSION

Tuberculosis patients might be more disadvantageous than the normal population in terms of the risk of exposure to severe acute respiratory syndrome coronavirus 2, but this does not cause an increase in the frequency and severity of coronavirus disease 2019 disease in active tuberculosis patients.

摘要

目的

结核病和2019冠状病毒病在具有相似风险因素的人群中更为常见。本研究旨在分享严重急性呼吸综合征冠状病毒2大流行期间活动性肺结核患者的数据。

材料与方法

筛选2019年11月1日至2020年4月20日期间结核病门诊的登记信息。对被诊断为活动性肺结核且同意参与研究的患者进行了一项包含7个问题的调查。

结果

共评估了309例活动性肺结核患者,患者的平均年龄为42.5±18.5岁,70%为男性。至少有一种合并症的患者比例为30.4%。我们研究人群中2019冠状病毒病的比例为1.9%;2019冠状病毒病患者中无一因临床恶化和/或呼吸衰竭而进入重症监护病房或死亡。另一方面,在此过程中宣布,全国共有146457例确诊为2019冠状病毒病,其中72%接受住院治疗,2%死亡,944例患者仍在重症监护病房接受治疗,其中490例进行了插管。研究组逆转录-聚合酶链反应检测的阳性率为20.0%,而伊斯坦布尔人群中的阳性率为20.3%。

结论

结核病患者在接触严重急性呼吸综合征冠状病毒2的风险方面可能比正常人群更不利,但这并不会导致活动性肺结核患者中2019冠状病毒病的发病率和严重程度增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4102/9450003/fb396d5870e0/ttj-23-1-58_f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4102/9450003/fb396d5870e0/ttj-23-1-58_f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4102/9450003/fb396d5870e0/ttj-23-1-58_f001.jpg

相似文献

1
Co-infection of COVID-19 and Tuberculosis.新型冠状病毒肺炎与结核病合并感染
Turk Thorac J. 2022 Jan;23(1):58-62. doi: 10.5152/TurkThoracJ.2022.21045.
2
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Severe Acute Respiratory Syndrome by SARS-CoV-2 Infection or Other Etiologic Agents Among Brazilian Indigenous Population: An Observational Study from the First Year of Coronavirus Disease (COVID)-19 Pandemic.巴西原住民中由严重急性呼吸综合征冠状病毒2感染或其他病原体引起的严重急性呼吸综合征:一项关于冠状病毒病(COVID)-19大流行第一年的观察性研究。
Lancet Reg Health Am. 2022 Apr;8:100177. doi: 10.1016/j.lana.2021.100177. Epub 2022 Jan 7.
5
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
6
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.一项评估静脉注射瑞维鲁单抗对比 COVID-19 重症肺炎、急性肺损伤或急性呼吸窘迫综合征患者最佳支持治疗的疗效和安全性的 III 期开放性标签、随机对照研究:一项随机对照试验研究方案的结构性总结。
Trials. 2020 Jul 13;21(1):639. doi: 10.1186/s13063-020-04548-z.
7
[Clinical Properties of COVID-19 Developed in the Patients with Tuberculosis].[结核病患者中新冠病毒病的临床特征]
Mikrobiyol Bul. 2022 Oct;56(4):722-728. doi: 10.5578/mb.20229609.
8
Tuberculosis结核病
9
Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy.评估抗 TNF 治疗的强直性脊柱炎患者 COVID-19 的频率和强度。
Turk J Med Sci. 2022 Apr;52(2):522-523. doi: 10.55730/1300-0144.5341. Epub 2022 Apr 14.
10
Pregnant women with severe or critical coronavirus disease 2019 have increased composite morbidity compared with nonpregnant matched controls.患有严重或危急 2019 冠状病毒病的孕妇与未怀孕的匹配对照相比,复合发病率增加。
Am J Obstet Gynecol. 2021 May;224(5):510.e1-510.e12. doi: 10.1016/j.ajog.2020.11.022. Epub 2020 Nov 20.

引用本文的文献

1
Bacterial co-infection in COVID-19: a call to stay vigilant.新冠病毒感染中的细菌合并感染:保持警惕的呼吁。
PeerJ. 2024 Sep 19;12:e18041. doi: 10.7717/peerj.18041. eCollection 2024.
2
The association of SARS-CoV-2 infection and tuberculosis disease with unfavorable treatment outcomes: A systematic review.严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)感染与结核病合并出现不良治疗结局的关联:一项系统评价
PLOS Glob Public Health. 2023 Jul 19;3(7):e0002163. doi: 10.1371/journal.pgph.0002163. eCollection 2023.
3
Changing Epidemiology of Respiratory Tract Infection during COVID-19 Pandemic.

本文引用的文献

1
Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.利福平与来特莫韦作为新型冠状病毒肺炎治疗中潜在的药物再利用候选药物:计算机模拟研究的见解
Pharmacol Rep. 2021 Jun;73(3):926-938. doi: 10.1007/s43440-021-00228-0. Epub 2021 May 10.
2
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.活动性肺结核、后遗症与 COVID-19 合并感染:49 例首批队列。
Eur Respir J. 2020 Jul 9;56(1). doi: 10.1183/13993003.01398-2020. Print 2020 Jul.
3
A Review of Coronavirus Disease-2019 (COVID-19).
新冠疫情期间呼吸道感染流行病学的变化
Antibiotics (Basel). 2022 Feb 25;11(3):315. doi: 10.3390/antibiotics11030315.
新型冠状病毒肺炎(COVID-19)概述。
Indian J Pediatr. 2020 Apr;87(4):281-286. doi: 10.1007/s12098-020-03263-6. Epub 2020 Mar 13.
4
In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus.中草药抗 2019 新型冠状病毒的计算机虚拟筛选
J Integr Med. 2020 Mar;18(2):152-158. doi: 10.1016/j.joim.2020.02.005. Epub 2020 Feb 20.
5
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病(COVID-19)疫情的特征及重要经验教训:来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
6
SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients.感染患者上呼吸道标本中的新型冠状病毒2型病毒载量
N Engl J Med. 2020 Mar 19;382(12):1177-1179. doi: 10.1056/NEJMc2001737. Epub 2020 Feb 19.
7
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情,该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
8
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.新型冠状病毒感染肺炎在中国武汉的早期传播动力学。
N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
10
The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China.新型冠状病毒持续的2019 - nCoV疫情对全球健康构成威胁——中国武汉最新的2019新型冠状病毒爆发。
Int J Infect Dis. 2020 Feb;91:264-266. doi: 10.1016/j.ijid.2020.01.009. Epub 2020 Jan 14.